|
Cardiovascular Devices from Medtronic Featured Prominently at EuroPCR
Cardiology Meeting in Paris May
25–28 Includes New Data on Resolute® Drug-Eluting Stent, IN.PACT Line of Drug-Eluting Balloons and CoreValve® Transcatheter
Aortic Valve
|
 |
May 20, 2010 -- Minneapolis --
Medtronic, Inc. (NYSE: MDT), announced today the schedule of important
clinical data presentations during EuroPCR, a major cardiology
meeting taking place May 25–28 in Paris at the Palais de Congrès.
The meeting will prominently feature several
of Medtronic’s innovative cardiovascular devices, including the
Resolute coronary drug-eluting stent, the IN.PACT line of coronary
and peripheral drug-eluting balloons, and the CoreValve transcatheter
aortic valve replacement system. “Medtronic is the only company with technological and therapeutic expertise in coronary and peripheral interventions as well as cardiac and vascular surgery,” said Scott Ward, senior vice president of Medtronic and president of the company’s CardioVascular business. “The
breadth and depth of our product portfolio and pipeline for
these specialties is unmatched. We are uniquely positioned
to work together with medical professionals across disciplines
and around the world to advance the treatment of cardiovascular
disease.”
EuroPCR 2010 is the first major medical meeting
for interventional cardiologists and other interventionalists since
Medtronic completed its acquisition of Invatec on April 21. The
program includes several presentations on the novel devices developed
by Invatec for the treatment of coronary and peripheral vascular
disease – most notably, the IN.PACT Admiral, Amphirion and Falcon
drug-eluting balloons, and the Mo.Ma proximal embolic protection
system. Highlights of the EuroPCR program for cardiovascular devices from Medtronic follow:
[note: All Central Europe Summer Time (Paris) and congress center locations.] EuroPCR 2010 / Paris Tuesday, May 25 (Day 1) - The
Great Debate – Transcatheter aortic valve implantation (TAVI):
from concept to evidence-driven practice
12:20 – 2:20 pm (Main Arena)
(supported with an unrestricted educational grant from Medtronic) - Hotline
2 – Endovascular late breaking trials
1:30 – 2:20 pm (Theatre Havane)
Starts with two presentations of clinical data on the Mo.Ma
proximal embolic protection system: “Armour trial – Final results” and “Proximal
endovascular clamping for carotid artery stenting: 1-year follow-up
of a prospective registry of 1,300 consecutive patients” - Hotline
3 – TAVI Facts, Figures and National Registries
3:00 – 4:05 pm (Main Arena)
Featuring new clinical data from TAVI registries in Belgium, France, Germany, Italy and the U.K. (all include the CoreValve system; the Italian registry includes on the CoreValve system) - Hotline
4 – Late Breaking Trials
4:05 – 5:35 pm (Main Arena)
Featuring one-year results of the RESOLUTE All-Comers study, the first randomized, head-to-head comparison of the Resolute zotarolimus-eluting and the Xience V everolimus-eluting coronary stents (the first presentation of the primary clinical and secondary angiographic outcomes)
Wednesday, May 26 (Day 2) - TAVI: mid- and long-term clinical outcomes
12:00 noon – 1:30 pm (Room 243)
Starts with “Stable durability and effectiveness at 2 years with the CoreValve transcatheter aortic valve”; also includes “Medium-term results of transcatheter aortic valve implantation with the CoreValve: the Italian Registry” (one
of the largest country-specific registries of CoreValve patients) - Emerging
technologies and therapies in endovascular interventions –
Drug-eluting balloon in peripheral vascular interventions
1:30 – 3:00 pm (Vendôme)
Includes “The value of drug-eluting balloons for below-the-knee interventions”(a
presentation of the Leipzig 100-patient single-center clinical
data on the IN.PACT Amphirion drug-eluting balloon) - Cardiovascular Innovation Pipeline @ EuroPCR
4:30 – 6:30 pm (Room 243)
Spans nine recent technological advances, including “Continuous sinusoid technology – the future of Medtronic’s stent pipeline” (based on the Integrity® bare-metal
stent)
Thursday, May 27 (Day 3) - TAVI: new insights from imaging
8:00 – 9:00 am (Room 253)
Includes “Serial echocardiographic evaluation of the CoreValve aortic bioprosthesis: the Italian Registry,” an
examination of left ventricular remodeling following
CoreValve implantation - What do Resolute All Comers data tell us about the treatment of complex disease and complex patients
12:00 noon – 1:30 pm (Theatre Havane)
(supported with an unrestricted educational grant from Medtronic) - From drug-eluting stent to drug-eluting balloon:
the role of drug-eluting balloons in percutaneous coronary intervention
4:30 – 6:00 pm (Theatre Havane)
Features the first presentation of the Homburg/Saar 23-patient single-center clinical data on the IN.PACT Falcon drug-eluting balloon for coronary in-stent restenosis; also includes additional presentations on the use of the IN.PACT line of drug-eluting balloons in coronary arteries, including small vessels, and peripheral applications (supported with an unrestricted educational grant from Medtronic)
In
the United States, the Resolute drug-eluting stent is
limited by U.S. federal law to investigational use only.
The Integrity bare-metal stent, the CoreValve transcatheter
aortic valve, and the IN.PACT Amphirion and Falcon drug-eluting
balloons are not available for sale or investigation
in the United States. All of these devices have received
the CE (Conformité Européenne) mark, making them widely
available outside the United States and Japan. The CardioVascular business at Medtronic is committed to advancing the treatment of coronary, peripheral, aortic and structural heart disease through collaboration with leading clinicians, researchers and scientists worldwide. About Medtronic
Medtronic, Inc. (www.medtronic.com),
headquartered in Minneapolis, is the global leader in medical technology – alleviating
pain, restoring health, and extending life for millions of people
around the world. Any forward-looking
statements are subject to risks and uncertainties such as those
described
in Medtronic’s periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
Source: Medtronic,
Inc.
|
